The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3′-untranslated region destabilization element can increase specificity

Journal of Gene Medicine

Volumn 10, Issue 7, 2008, Pages 744-753

  Särkioja, Merja ^a,b   Hakkarainen, Tanja ^a,b   Eriksson, Minna ^a,b   Ristimäki, Ari ^b   Desmond, Renee A ^c   Kanerva, Anna ^a,b   Hemminki, Akseli ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

3 UTR; Adenovirus; AU rich element; Cancer gene therapy; Cyclo oxygenase 2; Promoter

Indexed keywords

CYCLOOXYGENASE 2; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D; LUCIFERASE;

3' UNTRANSLATED REGION; ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS REPLICATION;

3' UNTRANSLATED REGIONS; ADENOVIRUS INFECTIONS, HUMAN; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DNA PRIMERS; GENE EXPRESSION REGULATION; HUMANS; LUCIFERASES; PLASMIDS; PROMOTER REGIONS (GENETICS); TRANSFECTION;

ADENOVIRIDAE; CYTOMEGALOVIRUS;

EID: 48949120132     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1193     Document Type: Article

References (46)

1. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
2. Glasgow JN, Bauerschmitz GJ, Curiel DT, et al. Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther 2004; 4: 1-14.
3. Harris JD, Lemoine NR. Strategies for targeted gene therapy. Trends Genet 1996; 12: 400-405.
4. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727.
5. Barker SD, Dmitriev IP, Nettelbeck DM, et al. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Ther 2003; 10: 1198-1204.
6. Saukkonen K, Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 2004; 4: 683-696.
7. Bauerschmitz GJ, Guse K, Kanerva A, et al. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1 A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 2006; 14: 164-174.
8. Casado E, Gomez-Navarro J, Yamamoto M, et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 2001; 7: 2496-2504.
9. Hirschowitz E, Hidalgo G, Doherty D. Induction of cyclooxygenase-2 in non-small cell lung cancer cells by infection with DeltaE1, DeltaE3 recombinant adenovirus vectors. Gene Ther 2002; 9: 81-84.
10. Liang Q, Yamamoto M, Curiel DT, et al. Noninvasive imaging of transcriptionally restricted transgene expression following intratumoral injection of an adenovirus in which the COX-2 promoter drives a reporter gene. Mol Imaging Biol 2004; 6: 395-404.
11. Nettelbeck DM, Rivera AA, Davydova J, et al. Cyclooxygenase-2 promoter for tumour-specific targeting of adenoviral vectors to melanoma. Melanoma Res 2003; 13: 287-292.
12. Ono HA, Davydova JG, Adachi Y, et al. Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer. J Gastroenterol 2005; 40: 31-42.
13. Yamamoto M, Alemany R, Adachi Y, et al. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001; 3: 385-394.
14. Yamamoto M, Davydova J, Wang M, et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003; 125: 1203-1218.
15. Shirakawa T, Hamada K, Zhang Z, et al. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells. Clin Cancer Res 2004; 10: 4342-4348.
16. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266: 12866-12872.
17. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: F181-F191.
18. Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002; 53: 35-57.
19. Telliez A, Furman C, Pommery N, et al. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Agents Med Chem 2006; 6: 187-208.
20. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 632-635.
21. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 2840-2855.
22. Sheng H, Shao J, Dubois RN. K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res 2001; 61: 2670-2675.
23. Cok SJ, Morrison AR. The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001; 276: 23179-23185.
24. Thiel A, Heinonen M, Rintahaka J, et al. Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells. J Biol Chem 2006; 281: 4564-4569.
25. Lasa M, Mahtani KR, Finch A, et al. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol 2000; 20: 4265-4274.
26. Dixon DA, Kaplan CD, McIntyre TM, et al. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem 2000; 275: 11750-11757.
27. Kruys V, Marinx O, Shaw G, et al. Translational blockade imposed by cytokine-derived UA-rich sequences. Science 1989; 245: 852-855.
28. Dean JL, Brook M, Clark AR, et al. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 1999; 274: 264-269.
29. Ahmed A, Thompson J, Emiliusen L, et al. A conditionally replicating adenovirus targeted to tumor cells through activated RAS/ P-MAPK-selective mRNA stabilization. Nat Biotechnol 2003; 21: 771-777.
30. Kanerva A, Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004; 110: 475-480.
31. Suzuki K, Fueyo J, Krasnykh V, et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001; 7: 120-126.
32. Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8: 449-458.
33. Kanerva A, Wang M, Bauerschmitz GJ, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002; 5: 695-704.
34. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761-3764.
35. Coe BP, Lockwood WW, Girard L, et al. Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer 2006; 94: 1927-35.
36. Chien PS, Mak OT, Huang HJ. Induction of COX-2 protein expression by vanadate in A549 human lung carcinoma cell line through EGF receptor and p38 MAPK-mediated pathway. Biochem Biophys Res Commun 2006; 339: 562-568.
37. Moriuchi M, Inoue H, Moriuchi H. Reciprocal interactions between human T-lymphotropic virus type 1 and prostaglandins: implications for viral transmission. J Virol 2001; 75: 192-198.
38. Symensma TL, Martinez-Guzman D, Jia Q, et al. COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression. J Virol 2003; 77: 12753-12763.
39. Zhu H, Cong JP, Yu D, et al. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci USA 2002; 99: 3932-3937.
40. Shao R, Karunagaran D, Zhou BP, et al. Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J Biol Chem 1997; 272: 32739-32742.
41. Bruder JT, Kovesdi I. Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J Virol 1997; 71: 398-404.
42. Schumann M. Dobbelstein M. Adenovirus-induced extracellular signal-regulated kinase phosphorylation during the late phase of infection enhances viral protein levels and virus progeny. Cancer Res 2006; 66: 1282-1288.
43. Creighton CJ, Bromberg-White JL, Misek DE, et al. Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol Cancer Res 2005; 3: 119-129.
44. Flint J, Shenk T. Viral transactivating proteins. Annu Rev Genet 1997; 31: 177-212.
45. Meier JL, Stinski MF. Regulation of human cytomegalovirus immediate-early gene expression. Intervirology 1996; 39: 331-342.
46. Spector DH. Activation and regulation of human cytomegalovirus early genes. Intervirology 1996; 39: 361-377.